In a departure from traditional cultivation methods, the cannabis industry is witnessing a shift towards synthetic production techniques, with companies exploring novel approaches to manufacturing cannabinoids like THC and CBD.
Among these pioneers is Boston- based Ginkgo Bioworks, which recently secured a groundbreaking deal with Cronos Group, a Canadian cannabis company, valued at around $100 million (about R1.8 billion).
Leveraging synthetic biology, Ginkgo aims to produce marijuana's active ingredients using genetically modified microorganisms, particularly yeast.
Much like yeast’s role in brewing beer, Ginkgo plans to genetically engineer yeast to convert a concoction of sugar, vitamins, and other nutrients into cannabinoids.
This process, conducted in large fermentation vats akin to those used in breweries, promises greater scalability, purity, and cost-efficiency compared to traditional cultivation methods.
Jess Leber, Ginkgo’s head of business…